Stocks Health care CHRS
NASDAQ · Health careCoherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc. brought in $53.6M of revenue over the twelve months to September 30, 2026, up 44.4% from a year earlier. It posted a net loss of $135.9M. At September 30, 2026 it held $53.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Coherus Oncology, Inc.
- Net worth
- Coherus Oncology, Inc. has a market value (market cap) of $126.4M at the latest share price, and shareholders' equity of $25.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- Over the 12 months to September 30, 2026: revenue $53.6M, net loss $135.9M.
- Cash flow
- In fiscal 2025 operations used $138.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Coherus Oncology, Inc.'s next report is expected around January 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Coherus Oncology, Inc. does
Coherus Oncology, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CHRS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $42.2M | $168M | $1.43 | n/a |
| 2024 | $26.4M | $28.5M | $0.25 | n/a |
| 2023 | $257.2M | -$237.9M | -$2.53 | -$175.2M |
| 2022 | $211M | -$291.8M | -$3.76 | -$243.2M |
| 2021 | $326.6M | -$287.1M | -$3.81 | -$38.7M |
| 2020 | $475.8M | $132.2M | $1.62 | $146.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CHRS ranks in Health care
Latest SEC filings
What Coherus Oncology, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 23% to $14.3M versus the same quarter last year; diluted EPS -$0.25 versus -$0.31.
- November 9, 2026
- October 29, 2026
- August 28, 2026Other event 8-K
- August 17, 2026
- August 17, 2026
- August 5, 2026
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 40% to $14.3M versus the same quarter last year; diluted EPS -$0.13 versus $2.57.
- August 5, 2026
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Coherus Oncology, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 5, 2026 | Newton Charles W.Director | Received as pay | 30,000 | - |
| June 5, 2026 | Wahlstrom MatsDirector | Received as pay | 30,000 | - |
| June 5, 2026 | O'Donnell-Tormey JillDirector | Received as pay | 30,000 | - |
| June 5, 2026 | Ryan Michael LeeDirector | Received as pay | 30,000 | - |
| June 5, 2026 | Newcomer Lee NisleyDirector | Received as pay | 30,000 | - |
| June 5, 2026 | Karachun Rita ADirector | Received as pay | 30,000 | - |
| June 5, 2026 | Satvat Ali J.Director | Received as pay | 30,000 | - |
| January 23, 2026 | Lanfear Dennis MPresident & CEO, Director | Received as pay | 375,000 | - |
Who owns CHRS
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Timothy G. Youngquist 2020 Irrevocable Trust13G, passive | 8.3% | May 15, 2026 |
| Evgeny Zaytsev ("Zaytsev")13G, passive with 5 related filers | 6.5% | November 4, 2025 |
Largest institutional holders
Insiders
9 insiders reported holding 1,391,971 shares in total, about $1.1M at the last price.
| Holder | Shares |
|---|---|
| Lanfear Dennis MPresident & CEO, Director | 1,048,235 |
| McMichael Bryan JChief Financial Officer | 133,736 |
| Karachun Rita ADirector | 30,000 |
| Satvat Ali J.Director | 30,000 |
| Newcomer Lee NisleyDirector | 30,000 |
| Newton Charles W.Director | 30,000 |
| O'Donnell-Tormey JillDirector | 30,000 |
| Ryan Michael LeeDirector | 30,000 |
| Wahlstrom MatsDirector | 30,000 |
Questions about CHRS
What does Coherus Oncology, Inc. do?
Coherus Oncology, Inc. is a company in the Health care sector, listed on NASDAQ as CHRS. Its shares trade on NASDAQ under the ticker CHRS.
What is Coherus Oncology, Inc.'s net worth?
Coherus Oncology, Inc. has a market value (market cap) of $126.4M at the latest share price, and shareholders' equity of $25.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Coherus Oncology, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $135.9M on revenue of $53.6M.
How much revenue does Coherus Oncology, Inc. make?
Over the twelve months to September 30, 2026 Coherus Oncology, Inc. reported revenue of $53.6M. That is 44.4% more than a year earlier.
When did Coherus Oncology, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Coherus Oncology, Inc.'s next earnings report?
Coherus Oncology, Inc.'s next report is expected around January 12, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CHRS with
Follow CHRS
Get an email when Coherus Oncology, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Coherus Oncology, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.